AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc. announced today that data from a study evaluating its Signature® LTx v2.0, a CE-marked IVD test, for the multiplex detection of fusion transcripts associated with ALL, AML and CML leukemia, will be presented at the upcoming Planet XMAP Europe being held September 28 – 29, 2011 in Vienna, Austria. Joanne Mason, Clinical Scientist at West Midlands Regional Genetics Laboratory, Birmingham, UK will present the results from its evaluation of Asuragen’s test and comparison of its performance to standard cytogenetic methods and other molecular methods.
